Brief: MorphoSys Completes Enrollment Of Phase 3 MANIFEST-2 Study Of Pelabresib, Results Expected By End Of 2023

Morphosys AG

05/04/2023 06:17

April 5 (Reuters) - MORPHOSYS AG  MORG.DE :
    * SAID ON TUESDAY: COMPLETES ENROLLMENT OF PHASE 3
MANIFEST-2
STUDY OF PELABRESIB IN MYELOFIBROSIS WITH TOPLINE RESULTS
EXPECTED BY END OF 2023
    * ENROLLMENT OF PHASE 3 FRONTMIND STUDY OF TAFASITAMAB IN
FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA IS ALSO COMPLETE

Source text for Eikon:  ID:nEQ75lP2sa 
Further company coverage:  MORG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))